FTT PET/CT in Pancreatic Neuroendocrine Tumors

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

NCT Number	NCT07114939
Lead Sponsor	Abramson Cancer Center at Penn Medicine Collaborators: University of Pennsylvania
Conditions	Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
Enrollment	12 participants
Start Date	2025-10-01
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-02